Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRB-401: Abecma in Relapsed/Refractory Multiple Myeloma
NCT02658929Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Dec 2015
- Primary completion
- Jul 2019
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of idecabtagene vicleucel in multiple myeloma (MM), sponsored by Celgene Corporation. Primary endpoints: Incidence of Adverse Events and Dose Limiting Toxicities. Started Dec 2015; status: completed.
02
Drugs
idecabtagene vicleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02658929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02658929.